Brought to you by 
Roche brings in RNAi capabilities through Alnylam deal' Arrowhead takes over deal
Jul 2007
Executive Summary
Alnylam Pharmaceuticals (develops medicines that turn off disease-causing genes) has granted Roche nonexclusive rights to its RNA interference (RNAi) platform. The Big Pharma is also buying Alnylam's Kulmbach, Germany, R&D site and will convert it into a Center of Excellence focusing on RNAi therapeutics.
Deal Industry
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- R+D and Marketing-Licensing
- Includes Contract
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com